Can-Fite BioPharma Ltd. agreed to sell 1.5 million American depositary shares to certain institutional investors in a registered direct offering to raise $6 million in gross proceeds.
The Israel based biotechnology company will sell an ADS plus a warrant to purchase one additional ADS for $4 each. The warrants will expire after five years and have an exercise price of $4 per ADS.
Can-Fite said in March that its potential liver cancer drug Namodenoson could not improve survival compared to placebo in a mid-stage study. However, patients who had a severe form of the disease and did not respond to prior treatments survived longer with the drug in comparison to those taking placebo.
Namodenoson has been granted the fast-track designation by the U.S. Food and Drug Administration, which expedites the review process for drugs that address a condition with a high unmet need.
Can-Fite expects to close the offering May 22, subject to closing conditions.
H.C. Wainwright & Co. is the exclusive placement agent for the offering.